- 101. CCL3L1
- [This gene plays a role in immunoregulatory and inflammatory processes. ( NCI )] (UMLS (NCI) C1332689) CCL3L1 Gene;
Chemokine (C-C Motif) Ligand 3-Like 1 Gene =Gene or Genome | - 136. CCNU/CTX/PCB/VP-16
- (UMLS (NCI) C0677792) =Therapeutic or Preventive Procedure
|
- 102. CCL4
- [This gene plays a role in inflammatory and antiviral responses. ( NCI )] (UMLS (NCI) C1337091) CCL4 Gene;
Chemokine (C-C Motif) Ligand 4 Gene;
=Gene or Genome ;
| - 137. CCNU/CTX/VCR
- (UMLS (NCI) C0054931) =Therapeutic or Preventive Procedure
|
- 103. CCL5
- [This cytokine is one of the major HIV-suppressive factors produced by CD8+ cells. It functions as one of the natural ligands for the chemokine receptor CCR5 and it suppresses in vitro replication of the R5 strains of HIV-1, which use CCR5 as a coreceptor. (from LocusLink) ( NCI )] (UMLS (NCI) C0072978) =Amino Acid, Peptide, or Protein; Immunologic Factor
| - 138. CCNU/CTX/VCR/VP-16
- (UMLS (NCI) C0257084) =Therapeutic or Preventive Procedure ;
|
- 104. CCL5
- [This gene plays a role in antiviral responses. ( NCI )] (UMLS (NCI) C1332691) CCL5 Gene;
Chemokine (C-C Motif) Ligand 5 Gene =Gene or Genome | - 139. CCNU/DBD/PCB/TG
- (UMLS (NCI) C0280695) =Therapeutic or Preventive Procedure
|
- 105. CCL7
- [Small Inducible Cytokine A7, encoded by the CCL7 gene, is a secreted chemokine which attracts macrophages during inflammation and metastasis. It is a member of the C-C subfamily of chemokines which are characterized by having two adjacent cysteine residues. The protein is an in vivo substrate of matrix metalloproteinase 2, an enzyme which degrades components of the extracellular matrix. (from LocusLink) ( NCI )] (UMLS (NCI) C0379885) =Amino Acid, Peptide, or Protein ;
| - 140. CCNU/DBD/PCB/TG/VCR
- (UMLS (NCI) C0279769) =Therapeutic or Preventive Procedure
|
- 106. CCL7
- [This gene plays a role in extracellular matrix modulation and inflammatory processes. ( NCI )] (UMLS (NCI) C1332692) CCL7 Gene;
Chemokine (C-C Motif) Ligand 7 Gene =Gene or Genome | - 141. CCNU/DFMO/PCB/VCR
- (UMLS (NCI) C0280770) =Therapeutic or Preventive Procedure
|
- 107. CCL8
- [This cytokine displays chemotactic activity for monocytes, lymphocytes, basophils and eosinophils. By recruiting leukocytes to sites of inflammation this cytokine may contribute to tumor-associated leukocyte infiltration and to the antiviral state against HIV infection. (from LocusLink) ( NCI )] (UMLS (NCI) C0379886) =Amino Acid, Peptide, or Protein ;
| - 142. CCNU/DHAD/VBL
- (UMLS (NCI) C0280663) =Therapeutic or Preventive Procedure
|
- 108. CCL8
- [This gene is involved in the modulation of immune functions. ( NCI )] (UMLS (NCI) C1332693) CCL8 Gene;
Chemokine (C-C Motif) Ligand 8 Gene =Gene or Genome | - 143. CCNU/DM/IDA
- (UMLS (NCI) C0796402) Dexamethasone/Idarubicin/Lomustine;
=Therapeutic or Preventive Procedure |
- 109. CCMMT
- [A very rare, usually benign neoplasm with perivascular epithelioid cell differentiation characterized by the presence of clear spindle cells arranged in fascicles and nests that usually affects young girls. Patients usually present with a painful abdominal mass. ( NCI )] (UMLS (NCI) C1333068) Clear Cell Myomelanocytic Tumor of the Falciform Ligament/Ligamentum Teres;
=Neoplastic Process ;
| - 144. CCNU/DOX/IFF
- (UMLS (NCI) C0279313) =Therapeutic or Preventive Procedure
|
- 110. CCNA2
- [Expressed at S-phase by human CCNA2 Gene (Cyclin A Subfamily) in all tissues tested (highest in testis), nuclear 432-amino acid 48.5-kD Cyclin A2 accumulates during G2, is abruptly destroyed at mitosis, controls the cell cycle, and promotes both G1/S and G2/M transitions. Inhibition of cyclin A synthesis or activity inhibits DNA synthesis. Highly conserved cyclins (proliferating cell nuclear antigens) regulate CDK kinases. Cyclin A interacts with CDK2 protein kinase and Ser/Thr kinase p34CDC2 (during G2/M) to form a holoenzyme complex; cyclin imparts substrate specificity to the complex. (from LocusLink, Swiss-Prot, OMIM, and NCI) ( NCI )] (UMLS (NCI) C0297674) =Amino Acid, Peptide, or Protein; Biologically Active Substance
| - 145. CCNU/DOX/NM
- (UMLS (NCI) C0279378) =Therapeutic or Preventive Procedure
|
- 111. CCNA2
- [This gene is involved in G1/S and G2/M transitions in the cell cycle. ( NCI )] (UMLS (NCI) C1332694) CCNA2 Gene;
Cyclin A2 Gene =Gene or Genome | - 146. CCNU/IFF/VBL
- (UMLS (NCI) C0278911) =Therapeutic or Preventive Procedure
|
- 112. CCNB
- [Cyclin B1 is essential for control of the G2/M transition and the gene is expressed predominantly in the G2/M phase of cell division. Complexed with p34(cdc2), cyclin B1 forms mitosis-promoting factor (MPF), a serine/threonine kinase holoenzyme complex. Cyclin B1 imparts substrate specificity to MPF. Phosphorylation of cyclin B1 regulates nuclear translocation of MPF during prophase, essential for the induction and coordination of M-phase events. During cell cycle progression, a change in PLK1 kinase activity appears to phosphorylate cyclin B1 and stimulate nuclear entry of cyclin B1. (from SWISS-PROT P14635, OMIM 123836, and NCI) ( NCI )] (UMLS (NCI) C0385333) =Amino Acid, Peptide, or Protein; Biologically Active Substance ;
| - 147. CCNU/IFN-A
- (UMLS (NCI) C0338112) =Therapeutic or Preventive Procedure ;
|
- 113. CCNB1
- [This gene plays a regulatory role in mitosis. ( NCI )] (UMLS (NCI) C1332695) CCNB1 Gene;
Cyclin B1 Gene =Gene or Genome | - 148. CCNU/MTX
- (UMLS (NCI) C0281441) =Therapeutic or Preventive Procedure
|
- 114. CCNB2
- [Cyclin B2, encoded by the CCNB2 gene, is a member of the cyclin family of CDK kinase regulatory subunits, specifically the B-type cyclins. Cyclin B2 is primarily associated with the Golgi region. Cyclin B2 is essential for the control of the cell cycle at the G2/M (mitosis) transition. Cyclin B2 interacts with the CDC2 protein kinase to form a serine/threonine kinase holoenzyme complex, activating and imparting substrate specificity to the complex. Cyclin B2 also binds to transforming growth factor beta RII and thus cyclin B2/CDC2 may play a key role in transforming growth factor beta-mediated cell cycle control. Cyclin B2 accumulates steadily during G2 and is abruptly destroyed at mitosis. Overexpression of cyclins B, resulting from different mechanisms, could contribute, through an alteration of the spindle checkpoint, to the chromosomal instability observed in cancer. (From LocusLink, PMID and NCI) ( NCI )] (UMLS (NCI) C0757880) Cyclin B2;
G2/Mitotic-Specific Cyclin B2;
=Amino Acid, Peptide, or Protein; Biologically Active Substance ;
| - 149. CCNU/MTX/PCB
- (UMLS (NCI) C0054385) =Therapeutic or Preventive Procedure
|
- 115. CCNB2
- [This gene is a mediator in cell cycle regulation. ( NCI )] (UMLS (NCI) C1332696) CCNB2 Gene;
Cyclin B2 Gene =Gene or Genome | - 150. CCNU/MTX/PRED/VP-16
- (UMLS (NCI) C0279187) =Therapeutic or Preventive Procedure
|
- 116. CCND1
- [This gene plays a role in the regulation of mitotic events. ( NCI )] (UMLS (NCI) C1413172) CCND1 Gene;
Cyclin D1 Gene =Gene or Genome | - 151. CCNU/MTX/VCR
- (UMLS (NCI) C0279503) =Therapeutic or Preventive Procedure
|
- 117. CCND2
- [Human G1/S-specific cyclin D2 protein (289 aa, 33 kD) is encoded by the human cyclin D2 (CCND2) gene. This protein is essential for control of the G1/S phase of the cell cycle. Cyclin D2 protein binds to the protein kinases CDK4 and CDK6 (which are also required for the G1/S transition) to form a serine/threonine kinase haloenzyme complex. Cyclin D2 protein both regulates these protein kinases and confers substrate specificity to this complex. It also interacts with the Rb tumor suppressor protein and plays a role in the phosphorylation of this protein. Cyclin D2 protein plays a role in the proliferation of gonadal cells and is associated with malignant transformation of these cells. High levels of this protein have been detected in both ovarian and testicular tumors. ( NCI )] (UMLS (NCI) C0214570) =Amino Acid, Peptide, or Protein; Biologically Active Substance ;
| - 152. CCNU/PCB/PRED/VBL
- (UMLS (NCI) C0056635) =Therapeutic or Preventive Procedure
|
- 118. CCND2
- [This gene is involved in the regulation of the G1/S phase of the cell cycle. ( NCI )] (UMLS (NCI) C1413173) CCND2 Gene;
Cyclin D2 Gene =Gene or Genome | - 153. CCNU/PCB/TG/VCR
- (UMLS (NCI) C0393021) =Therapeutic or Preventive Procedure
|
- 119. CCNE1
- [Cyclin E1, a protein encoded by the CCNE1 gene, forms a complex with and functions as a regulatory subunit of CDK2, whose activity is essential for the control of the cell cycle at the G1/S (start) transition. Cyclin E1 accumulates at the G1-S phase boundary and phosphorylation by CDK2 triggers its release from CDK2 and degradation. Overexpression of this gene is observed in many tumors, which results in chromosome instability and may contribute to tumorigenesis. Cyclin E1 is associated with and involved in the phosphorylation of NPAT protein (nuclear protein mapped to the ATM locus), which participates in cell-cycle regulated histone gene expression and plays a critical role in promoting cell-cycle progression in the absence of pRB. Two isoforms, E1L and E1S, are produced by alternative splicing and E1S cannot complex with CDK2. Cyclin E1 is highly expressed in testis and placenta with low levels in bronchial epithelial cells. (NCI) ( NCI )] (UMLS (NCI) C1259807) Cyclin E;
Cyclin E1;
Cyclin Es;
Cyclin Et;
=Amino Acid, Peptide, or Protein; Biologically Active Substance ;
◊ [This gene regulates the G1/S phase of the cell cycle by cyclin expression. ( NCI )] (UMLS (NCI) C1332697) CCNE1 Gene; Cyclin E1 Gene Gene or Genome | - 154. CCNU/PCB/VCR
- (UMLS (NCI) C0070167) =Therapeutic or Preventive Procedure ;
|
- 120. CCNE2
- [Conserved human CCNE2 Gene (Cyclin E Subfamily) encodes distinct nuclear isoforms of Cyclin E2: 1 (full-length 404-aa, 46.8-kD and 47% identical to E1), 2 (359-aa), and 3. Lacking 45 internal residues in the cyclin box, variant 2 does not bind CDK2. Frameshifted truncated variant 3 lacks 112 N-terminal residues. Imparting substrate specificity, short-lived regulatory E2 interacts with CDKs2/3, forms a holoenzyme, controls DNA synthesis, and regulates G1/S. CDK2 phosphorylation of E2 triggers release and likely ubiquitinated degradation. E2 interacts with CDK inhibitors CIP/KIP, which bind and inhibit E2/CDK2. Cyclins E1, E2 may be rate-limiting for G1 progression. (from LocusLink, Swiss-Prot, OMIM, and NCI) ( NCI )] (UMLS (NCI) C0760775) CCNE2 Protein;
Cyclin E2;
G1/S-Specific Cyclin E2 =Amino Acid, Peptide, or Protein | - 155. CCNU/PRDL/VCR
- (UMLS (NCI) C0279265) =Therapeutic or Preventive Procedure
|
- 121. CCNE2
- [This gene regulates the G1/S phase of the cell cycle. ( NCI )] (UMLS (NCI) C1332698) CCNE2 Gene;
Cyclin E2 Gene =Gene or Genome | - 156. CCNU/PRED/VCR
- (UMLS (NCI) C0279300) =Therapeutic or Preventive Procedure
|
- 122. CCNU
- (UMLS (NCI) C0687700) =Organic Chemical; Pharmacologic Substance
| - 157. CCNU/VCR
- (UMLS (NCI) C0281541) =Therapeutic or Preventive Procedure
|
- 123. CCNU/CDDP/CTX/DOX/VCR
- (UMLS (NCI) C0056274) =Therapeutic or Preventive Procedure
| - 158. CCR
- [ ] (UMLS (CSP) C1328853) =Amino Acid, Peptide, or Protein; Immunologic Factor; Receptor
|
- 124. CCNU/CDDP/CTX/VCR/VP-16
- (UMLS (NCI) C0280557) =Therapeutic or Preventive Procedure
| - 159. CCR1
- [This gene is involved in immune cell mobilization to promote pro-inflammatory responses; further, the gene plays a role in chemotaxis. ( NCI )] (UMLS (NCI) C1332699) CCR1 Gene;
Chemokine (C-C Motif) Receptor 1 Gene =Gene or Genome |
- 125. CCNU/CDDP/VCR
- (UMLS (NCI) C0280773) =Therapeutic or Preventive Procedure
| - 160. CCR10
- [This gene is involved in the regulation of T cell-mediated inflammatory skin reactions and angiogenesis. ( NCI )] (UMLS (NCI) C1333692) CCR10 Gene;
Chemokine (C-C Motif) Receptor 10 Gene;
=Gene or Genome |
- 126. CCNU/CLB/VP-16
- (UMLS (NCI) C0279934) =Therapeutic or Preventive Procedure
| - 161. CCR5
- [This gene is involved in G protein-coupled signal transduction and chemotaxis. ( NCI )] (UMLS (NCI) C1332700) CCR5 Gene;
Chemokine (C-C Motif) Receptor 5 Gene =Gene or Genome |
- 127. CCNU/CTX/DOX/MTX
- (UMLS (NCI) C0065473) =Therapeutic or Preventive Procedure
| - 162. CCR6
- [This gene is involved in B-cell differentiation, maturation, and the recruitment of cells during inflammatory responses. ( NCI )] (UMLS (NCI) C1332701) CCR6 Gene;
Chemokine (C-C Motif) Receptor 6 Gene =Gene or Genome |
- 128. CCNU/CTX/DOX/PRED/VCR
- (UMLS (NCI) C0280552) =Therapeutic or Preventive Procedure
| - 163. CCR8
- [Chemokine (C-C Motif) Receptor 8, encoded by the CCR8 gene, is a member of the beta chemokine receptor family and a seven transmembrane protein similar to G protein-coupled receptor. This receptor is expressed preferentially in the thymus. I-309, thymus activation-regulated cytokine (TARC) and macrophage inflammatory protein-1 beta (MIP-1 beta) are ligands of this receptor. This receptor and its ligands regulate monocyte chemotaxis and thymic cell apoptosis. More specifically, this receptor may contribute to the proper positioning of activated T cells within the antigenic challenge sites and specialized areas of lymphoid tissues. (From LocusLink and NCI) ( NCI )] (UMLS (NCI) C1307911) Chemokine (C-C Motif) Receptor 8;
Chemokine (C-C) Receptor 8;
Chemokine (C-C) Receptor-Like 2;
CKRL1;
CKR-L1;
CMKBR8;
CMKBRL2;
CY6;
GPR-CY6;
TER1 =Amino Acid, Peptide, or Protein; Receptor ◊ [This gene plays a role in the regulation of chemotaxis and apoptosis. ( NCI )] (UMLS (NCI) C1332702) CCR8 Gene; Chemokine (C-C Motif) Ligand 8 Gene Gene or Genome |
- 129. CCNU/CTX/DOX/VCR
- (UMLS (NCI) C0054932) =Therapeutic or Preventive Procedure
| - 164. CCR9
- [This gene plays a role in thymocyte recruitment and development. ( NCI )] (UMLS (NCI) C1332703) CCR9 Gene;
Chemokine (C-C Motif) Receptor 9 Gene =Gene or Genome |
- 130. CCNU/CTX/DOX/VCR/VP-16
- (UMLS (NCI) C0280585) =Therapeutic or Preventive Procedure
| - 165. CCRG-81045
- (UMLS (NCI) C0108742) =Organic Chemical; Pharmacologic Substance ;
|
- 131. CCNU/CTX/L-PAM/PRDL/VCR
- (UMLS (NCI) C0280095) =Therapeutic or Preventive Procedure
| - 166. CCRL1
- [This gene plays a role in monocyte chemotaxis. ( NCI )] (UMLS (NCI) C1332704) CCRL1 Gene;
Chemokine (C-C Motif) Receptor-Like 1 Gene =Gene or Genome |
- 132. CCNU/CTX/MTX
- (UMLS (NCI) C0065772) =Therapeutic or Preventive Procedure ;
| - 167. CCRL2
- [Chemokine (C-C Motif) Receptor-Like 2, encoded by the CCRL2 gene, is a seven transmembrane chemokine receptor like protein that is most closely related to CCR1. Chemokines and their receptors mediated signal transduction are critical for the recruitment of effector immune cells to the site of inflammation. This gene is expressed at high levels in primary neutrophils and primary monocytes, and is further upregulated on neutrophil activation and during monocyte to macrophage differentiation. The function of this gene is unknown. (From LocusLink, OMIM, and NCI) ( NCI )] (UMLS (NCI) C1332649) CCRL2 Protein;
Chemokine (C-C Motif) Receptor-Like 2;
CKRX;
CRAM-A;
CRAM-B;
HCR;
=Amino Acid, Peptide, or Protein; Biologically Active Substance ◊ [This gene is involved in the activation and mobilization of immune cells in response to inflammatory stimuli. ( NCI )] (UMLS (NCI) C1332705) CCRL2 Gene; Chemokine (C-C Motif) Receptor-Like 2 Gene; Gene or Genome |
- 133. CCNU/CTX/MTX/VCR
- (UMLS (NCI) C0054929) =Therapeutic or Preventive Procedure
| - 168. CCSK
- [A rare type of kidney cancer. Clear cell sarcoma can spread from the kidney to other organs, most commonly the bone, but also including the lungs, brain, and soft tissues of the body. ( NCI )] (UMLS (NCI) C0334488) =Neoplastic Process
|
- 134. CCNU/CTX/PCB/PRED/VCR
- (UMLS (NCI) C0280074) =Therapeutic or Preventive Procedure
| - 169. CCSTL
- [A rare benign mesenchymal lung tumor arising from perivascular cells with epithelioid differentiation. It is composed of round or oval cells with abundant clear or eosinophilic cytoplasm and distinct cell borders. The vast majority of patients are asymptomatic and the tumors are discovered incidentally. Excision is curative. ( NCI )] (UMLS (NCI) C1333065) Clear Cell-Sugar-Tumor of Lung;
Clear Cell-Sugar-Tumor of the Lung;
Lung Clear Cell Tumor;
Sugar Tumor =Neoplastic Process ;
|
- 135. CCNU/CTX/PCB/VCR
- (UMLS (NCI) C0071317) =Therapeutic or Preventive Procedure
| |
home
